FDA Approves Replimune's Tudriqev for Advanced Melanoma After Two Previous Rejections
On Aug 6, the FDA granted accelerated approval to Replimune’s Tudriqev (vusolimogene oderparepvec-wtpg) with nivolumab for adults with unresectable advanced cutaneous melanoma that progressed after PD-1 therapy. The decision follows two prior FDA rejections. In IGNYTE, objective response rate was 24.2% (median duration 14.1 months).
How this was made
The 30-second read
Why it matters
The approval provides a new treatment option outside clinical trials, but the article stresses accelerated approval based on objective response rate and duration, with continued approval contingent on confirmatory Phase 3 IGNYTE-3 overall survival results.
Market read
A concrete FDA regulatory milestone for REPL, but the evidence package remains response-rate driven, keeping confirmatory-trial risk central for valuation.
What to watch
Commercial adoption depends on specialized image-guided intratumoral administration, insurer coverage timing, and safety logistics for a modified herpes virus, which can slow revenue ramp despite approval.
Background
FDA reversed two prior complete response letters for Replimune’s oncolytic virus immunotherapy Tudriqev, now approved with nivolumab for unresectable advanced cutaneous melanoma after PD-1 regimen progression.
Ticker impact
FDA granted accelerated approval for Tudriqev (vusolimogene oderparepvec-wtpg) in combination with nivolumab for advanced melanoma after two prior rejections.
Likely positive bias near-term, with volatility driven by expectations for confirmatory Phase 3 outcomes and commercial uptake constraints (center capability, coverage).
The article is a first-time FDA approval reversal after two complete response letters, but it explicitly notes continued approval depends on confirmatory survival benefit verification.
Market effects
Supports sentiment for oncolytic virus immunotherapies and combination checkpoint strategies, while highlighting the FDA’s bar for randomized controls in single-arm designs.
Access may initially concentrate around metropolitan academic centers with image-guided intratumoral injection capability.
Reinforces FDA accelerated-approval pathways in oncology, potentially influencing how similar programs structure confirmatory trials internationally.
Counterpoint
Because the label is accelerated and based on tumor response without proven survival benefit, the market may overprice near-term upside until IGNYTE-3 survival data de-risks the program.
Key entities
- companyReplimune
Company whose Tudriqev received FDA accelerated approval after two prior rejections.
- drugTudriqev (vusolimogene oderparepvec-wtpg)
Injected virus-based immunotherapy approved with nivolumab for advanced melanoma after PD-1 progression.
- drugNivolumab
Checkpoint inhibitor used in combination with Tudriqev in the approved regimen.
- clinical_trialIGNYTE-3
Ongoing Phase 3 confirmatory trial randomizing about 400 patients with overall survival as the primary endpoint.
